<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052531</url>
  </required_header>
  <id_info>
    <org_study_id>AP-TRPV1_PII-01</org_study_id>
    <nct_id>NCT02052531</nct_id>
  </id_info>
  <brief_title>Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus</brief_title>
  <official_title>A Phase II, Single Center, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of PAC-14028 Cream in Dermal Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amorepacific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to find a clinically appropriate dose of PAC-14028 cream by
      comparatively evaluating the efficacy and safety of PAC-14028 cream of Amorepacific
      Corporation in patients with dermal pruritus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline through Study Day 28</time_frame>
    <description>Patient reported outcome of pruritis measurement on a change in visual analog scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment success rate</measure>
    <time_frame>Baseline through Study Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in specified symptom sum score (SRRC) Index</measure>
    <time_frame>Baseline through Study Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transepidermal water loss</measure>
    <time_frame>Baseline through Study Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin hydration</measure>
    <time_frame>Baseline through Study Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Skin Pruritus</condition>
  <arm_group>
    <arm_group_label>PAC-14028 cream 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 cream 0.3%, twice daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 cream 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 cream 1.0%, twice daily for 28days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle, twice daily for 28days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028</intervention_name>
    <description>Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks</description>
    <arm_group_label>PAC-14028 cream 0.3%</arm_group_label>
    <arm_group_label>PAC-14028 cream 1.0%</arm_group_label>
    <other_name>PAC-14028 Cream 0.3%</other_name>
    <other_name>PAC-14028 Cream 1.0%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Participants received topical Vehicle twice daily for 4 weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Vehicle of PAC-14028 Cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients at the age of 20 to 65 years old (both inclusive)

          -  Pruritus test â‰¥ 5cm (10cm Visual Analogue Scale [VAS]) at baseline

          -  Eczema or dry skin on the study drug application site

          -  Women of childbearing potential should have a negative urine pregnancy test at
             screening and agree to employ an effective method of birth control (surgical
             sterilization or oral contraceptives, barrier method with spermicides, intrauterine
             device, etc.) during the study period.

          -  Voluntarily signed written informed consent forms for study participation.

        Exclusion Criteria:

          -  Pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or
             neuropathic causes rather than as a skin disease.

          -  Chronic skin diseases such as malignant tumor or chronic urticaria, among skin
             diseases.

          -  Simple pruritus caused by allergic substances such as scabies or insect bites.

          -  Presence of symptoms of generalized infection at the time of study participation.

          -  Previous local treatment or antibiotics administration for pruritus within 7 days
             prior to study participation.

          -  Previous use of oral steroids within 1 month and local steroids within 2 weeks prior
             to study participation.

          -  History of physical treatment for pruritus, including phototherapy, within 1 month
             prior to study participation.

          -  Patients who are treated with prohibited concomitant drugs or considered to inevitably
             require treatment with prohibited concomitant drugs during the study period.

          -  Renal function impairment with creatinine level

          -  Hepatic function impairment with aspartate aminotransferase (AST)/ alanine
             aminotransferase (ALT)

          -  Pregnant and lactating women

          -  Participation in another clinical study within 1 month prior to screening.

          -  Patients considered ineligible for study participation by the principal investigator
             or sub-investigator for other reasons; pruritus due to other medical (liver disease,
             renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Han Kim, MD,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyu-Han Kim</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>September 11, 2015</last_update_submitted>
  <last_update_submitted_qc>September 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

